Search clinical trials for: pegylated interferon alfa

Total 4489 results

M.D. Anderson Cancer Center

Withdrawn

Reactogenicity, Immunogenicity of Trivalent Influenza Vaccine With Recombinant Interferon Alpha Among Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Merck Sharp & Dohme LLC

Completed

PegIntron Treatment of Chronic Hepatitis B e Antigen-Positive Patients (P05170/MK-4031-327)

Hepatitis B, Chronic
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Pegylated Interferon Lambda With and Without Daclatasvir, Compared to Pegylated Interferon Alfa, Plus Ribavirin in Subjects With Hepatitis C Genotype 2 and 3 (PRINCIPAL)

Hepatitis C Virus (HCV)

Australia, Belgium, France, Italy, Japan, Korea, Republic of, Mexico, Russian Federation, Taiwan, United States, Chile, Hong Kong, Argentina, Netherlands, United Kingdom, Singapore, New Zealand, Finland, Greece
Hoffmann-La Roche

Completed

The Individualized Management With Pegylated-interferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Offering Viral Eradication: A Study of Pegylated-interferon Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C (CHC) Non-genotype 2/3 (IMPROVE) (IMPROVE)

Hepatitis C, Chronic

Canada, United States
Janssen-Cilag International NV

Completed

Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C

Genotype 1 Chronic Hepatitis C

Russian Federation
Janssen Infectious Diseases BVBA
Vertex Pharmaceuticals Incorporated

Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Genotype 1 Chronic Hepatitis C | Treatment Naive

United States, Australia, France, Poland, United Kingdom, Belgium, Germany, Spain, Sweden, Brazil, Austria, Ireland, Mexico
Tibotec BVBA

Completed

An Exploratory Study of Telaprevir in Treatment-Naive Participants With Chronic Genotype 4 Hepatitis C Virus Infection

Hepatitis C
Ullevaal University Hospital
Schering-Plough

Completed

14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

Hepatitis C Virus Infection

Norway
National Taiwan University Hospital
National Science Council, Taiwan; Department of Health, Executive Yuan, R.O...

Completed

Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin

Hemodialysis | Chronic Hepatitis C

Taiwan
Bristol-Myers Squibb

Completed

Safety and Efficacy Study of Daclatasvir (BMS-790052) Plus Pegylated Interferon-Alfa 2a and Ribavirin in Patients Coinfected With Untreated Hepatitis C Virus and HIV Virus

Hepatitis C, Genotype 1

United States, Australia, France, Germany, Spain, Canada, Puerto Rico, Argentina, Brazil, Russian Federation, United Kingdom, Italy, Belgium
Hoffmann-La Roche

Completed

A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C

Hepatitis C, Chronic

Georgia
Bausch Health Americas, Inc.

Completed

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-Naive

Chronic Hepatitis C
National Taiwan University Hospital
National Science Council, Taiwan

Completed

Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients

Hepatitis C, Chronic

Taiwan
Enyo Pharma

Completed

A Study of the Oral Farnesoid X Receptor Modulator EYP001a to Assess Its Safety and Anti-viral Effect in Chronic Hepatitis B Patients in Combination With Pegylated Interferon alpha2a Alone and With Entecavir

Hepatitis B, Chronic

Hong Kong, Korea, Republic of, Taiwan
National Cancer Institute (NCI)
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy

HIV Infection

United States
Yonsei University

Completed

A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon

Chronic Hepatitis B

Korea, Republic of
HepNet Study House, German Liverfoundation
Hannover Medical School

Terminated

Study to Assess the Efficacy of 12 Versus 24 Weeks of Extended Treatment in HCV-Genotype 2/3 Patients (OPTEX2/3)

Hepatitis C, Chronic

Germany
Biolex Therapeutics, Inc.

Completed

Study of Safety, Tolerability, and Anti-Viral Effect of Locteron Compared to PEG-Intron in Patients With Chronic Hepatitis C (PLUS)

Hepatitis C

United States
Replicor Inc.

Completed

Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B

Hepatitis B, Chronic
Merck Sharp & Dohme LLC

Completed

Extended Treatment With PEG-Intron® and Rebetol® in Patients With Genotype 1 Chronic Hepatitis C and Slow Virologic Response (Study P03685)

Hepatitis C, Chronic
Janssen-Cilag International NV

Completed

An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation (REPLACE)

Chronic Hepatitis C Virus (HCV) Infection

France, United Kingdom, Spain, Germany, Belgium, Austria
Hoffmann-La Roche

Completed

Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists)

Chronic Hepatitis C

Germany
Göteborg University
Hoffmann-La Roche

Terminated

Combination Therapy With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 2 or 3 Infection Who Previously Have Relapsed After Therapy With Pegylated Interferon and Ribavirin (RelapC)

Chronic Hepatitis C

Sweden
Hoffmann-La Roche

Completed

A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols

Hepatitis C, Chronic

Spain, United States, Germany, Canada, Austria, France
Merck Sharp & Dohme LLC

Terminated

Efficacy of Peginterferon Alfa-2b (SCH 054031) vs Glycyrrhizin in Interferon (IFN)-Treated Patients With Chronic Hepatitis C and F2/F3 Liver Fibrosis (P04773)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC

Completed

Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209)

Hepatitis C | Hepatitis C, Chronic
University of California, San Francisco
California HIV/AIDS Research Program

Completed

Treatment of Acute Hepatitis C Virus in HIV Co-Infection

HIV Infections | Hepatitis C | Human Immunodeficiency Virus

United States
Kirby Institute
Merck Sharp & Dohme LLC

Completed

A Collaborative Trial in Injectors of Individualized Treatment for Genotype 2/3 (ACTIVATE)

Hepatitis C, Chronic

Australia, Canada, United Kingdom, Belgium, Germany, Norway, Switzerland
Sociedad Andaluza de Enfermedades Infecciosas

Completed

Retreatment With High Doses of pegIFN Alfa-2a and Ribavirin of Previous Nonresponders HIV-coinfected Patients With Cirrhosis Due to HCV 1-4

Liver Cirrhosis | HIV Infection | Hepatitis C Virus

Spain
M.D. Anderson Cancer Center

Completed

Pegasys® in Patients With Myeloproliferative Diseases

Myeloproliferative Disorders

United States
Ochsner Health System
NewLink Genetics Corporation

Unknown

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

Melanoma

United States
Thomas Stauffer Larsen

Completed

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

Denmark
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

Brain and Central Nervous System Tumors

United States
Queen Mary University of London
Nottingham University Hospitals NHS Trust; Barts & The London NHS Trust; Janssen-Cilag... and other collaborators

Completed

Telaprevir in Genotype 3 HCV (TIG3)

Hepatitis C

United Kingdom
University of Calgary
Canadian Institutes of Health Research (CIHR); Roche Pharma AG

Completed

Pegylated Interferon Plus Ribavirin in the Treatment of Active and Past Intravenous Drug Users Infected With Hepatitis C

Hepatitis c

Canada
Kirby Institute
National Institutes of Health (NIH); The University of New South Wales

Completed

Australian Trial in Acute Hepatitis C

Hepatitis C

Australia
Merck Sharp & Dohme LLC

Completed

Pegylated Interferon (PEG-IFN) Alfa-2b and Low Dose Ribavirin for the Treatment of Chronic Hepatitis C Patients With Genotype 1 High Viral Load and Low Body Weight (Study P05172)(COMPLETED)

Hepatitis C, Chronic
Merck Sharp & Dohme LLC
Bioikos Ambiente Srl

Completed

Evaluation of Peginterferon Alfa-2b Monotherapy and Combination With Ribavirin in Participants With Acute Hepatitis C (P03552/MK-4031-137)

Hepatitis C
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC

Completed

Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine

Melanoma

United States
King Abdulaziz Medical City
King Faisal Specialist Hospital & Research Center; Riyadh Military Hospital

Completed

Peginterferon Alfa-2a Plus Ribavirin Combination Treatment in Chronic Hepatitis C Post-Renal Transplant Patients

Chronic Hepatitis C | Renal Transplant

Saudi Arabia
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

Hepatitis C

United States
National Taiwan University Hospital
National Science Council, Taiwan; Department of Health, Executive Yuan, R.O...

Completed

Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
National Institute of Allergy and Infectious Diseases...

Completed

A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Three Preparations of Low-Dose Oral Alpha Interferon in HIV-Infected Patients With CD4+ Counts >= 50 and <= 350 Cells/mm3

HIV Infections

United States
M.D. Anderson Cancer Center
Vertex Pharmaceuticals Incorporated

Terminated

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

Infection

United States
Hospices Civils de Lyon
Novartis

Unknown

Nilotinib ± Peg-IFN for First Line Chronic Phase CML Patients (PETALs)

Chronic Myeloid Leukemia

France
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys® With and Without Copegus® in Hepatitis C

Chronic Hepatitis C

Austria, France, Germany, United Kingdom
Bausch Health Americas, Inc.

Completed

Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive (VISER2)

Chronic Hepatitis C

United States, Spain, Italy, Australia, Canada, Poland, Puerto Rico, Russian Federation, Argentina, France, Israel, United Kingdom
Arbutus Biopharma Corporation

Active, not recruiting

Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B Infection

Chronic Hepatitis b

United States, Korea, Republic of, Hong Kong, Taiwan, Australia, Moldova, Republic of, Ukraine
ANRS, Emerging Infectious Diseases
Roche Pharma AG

Unknown

A Randomized Study to Assess the Loss of HbsAg After a 48-week Treatment Period With Pegylated Interferon Alpha 2a in Patients With Chronic Hepatitis B (PEGAN)

Chronic Hepatitis B | AgHbs Negativation

France
Hoffmann-La Roche

Completed

A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Hepatitis B, Chronic

Italy

3

Subscribe